Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

29.85
+0.14000.47%
Post-market: 29.850.00000.00%16:20 EDT
Volume:1.23M
Turnover:36.71M
Market Cap:3.80B
PE:-7.73
High:31.47
Open:30.17
Low:29.32
Close:29.71
52wk High:31.74
52wk Low:10.55
Shares:127.33M
Float Shares:89.84M
Volume Ratio:1.18
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:8.19
PE(LYR):-9.07

Loading ...

Arcus Biosciences shareholders re-elect Class II directors at annual meeting

Reuters
·
Jun 13

Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?

Simply Wall St.
·
Jun 12

Mizuho Securities Sticks to Its Buy Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Jun 11

Arcus Biosciences grants new hire options for 2,850 shares, RSUs for 1,450 shares under inducement plan

Reuters
·
Jun 10

Arcus Biosciences Initiated at Outperform by LifeSci Capital

Dow Jones
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jun 04

Arcus enters clinical trial collaboration, supply agreement with Bristol Myers

TIPRANKS
·
Jun 03

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

Dow Jones
·
Jun 03

Arcus Biosciences, Bristol Myers Squibb team up to test casdatifan combo in kidney cancer trial

Reuters
·
Jun 03

Arcus Biosciences - Announces Clinical Trial Collaboration With Bristol Myers Squibb

THOMSON REUTERS
·
Jun 03

Arcus Biosciences - to Supply Casdatifan for Phase 1/2 Rosetta Rcc-208 Trial

THOMSON REUTERS
·
Jun 03

Arcus Biosciences - to Initiate Phase 3 First-Line Metastatic Ccrcc Study by Year-End 2026

THOMSON REUTERS
·
Jun 03

Arcus Biosciences - Each Company Retains Development and Commercial Rights to Their Assets

THOMSON REUTERS
·
Jun 03

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination With Pd‑L1/Vegf‑a Bispecific Immunomodulator to Treat Kidney Cancer

THOMSON REUTERS
·
Jun 03

Arcus Biosciences Chief Accounting Officer Alexander Azoy disposes of 2,562 common shares for $66,029.72

Reuters
·
Jun 02

Arcus Biosciences to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
May 27

Arcus Biosciences Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 18

Arcus Biosciences assumed with a Buy at Truist

TIPRANKS
·
May 18

U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals

Reuters
·
May 18

Arcus CFO Robert C. Goeltz II disposes 7,763 shares worth $198,913.69

Reuters
·
May 13